These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329 [TBL] [Abstract][Full Text] [Related]
23. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959 [TBL] [Abstract][Full Text] [Related]
24. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987 [TBL] [Abstract][Full Text] [Related]
25. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome. Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377 [TBL] [Abstract][Full Text] [Related]
30. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J; J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235 [TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises? Efthimiadis A Angiology; 2008; 59(2 Suppl):62S-4S. PubMed ID: 18628276 [TBL] [Abstract][Full Text] [Related]
32. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Miedema I; Uyttenboogaart M; Koopman K; De Keyser J; Luijckx GJ Cerebrovasc Dis; 2010 Feb; 29(3):263-7. PubMed ID: 20090317 [TBL] [Abstract][Full Text] [Related]
33. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315 [TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833 [TBL] [Abstract][Full Text] [Related]
35. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Leker RR; Khoury ST; Rafaeli G; Shwartz R; Eichel R; Tanne D; Stroke; 2009 Jul; 40(7):2581-4. PubMed ID: 19407227 [TBL] [Abstract][Full Text] [Related]
36. [Clinical trials with rosuvastatin: efficacy and safety of its use]. Schweiger C Ital Heart J; 2003 Dec; 4 Suppl 7():33S-46S. PubMed ID: 14983745 [TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
39. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M; Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541 [TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong. Lee VW; Chau TS; Leung VP; Lee KK; Tomlinson B Chin Med J (Engl); 2009 Dec; 122(23):2814-9. PubMed ID: 20092783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]